SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Instil Bio, Inc. (TIL) has a negative trailing P/E of -0.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -125.43%.
Criteria proven by this page:
- VALUE (20/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.8); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -125.43%); analyst consensus target implies downside from the current price ($7.00, 17.1%).
- Trailing Earnings Yield -125.43% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $7.00 (-17.1% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
20/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — TIL
Valuation Multiples
P/E (TTM)-0.8
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.50
P/S Ratio0.00
EV/EBITDA-2.0
Per Share Data
EPS (TTM)$-10.52
Book Value / Share$16.79
Revenue / Share$0.00
FCF / Share$-5.40
Yields & Fair Value
Earnings Yield-125.43%
Dividend Yield0.00%
Analyst Target$7.00 (-17.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-525.2 |
0.00 |
420.80 |
0.00 |
- |
| 2020 |
-89.8 |
-0.19 |
11.59 |
24,564.72 |
- |
| 2021 |
-11.6 |
-0.03 |
3.27 |
0.00 |
- |
| 2022 |
-0.4 |
-0.02 |
0.22 |
0.00 |
- |
| 2023 |
-0.3 |
0.01 |
0.22 |
0.00 |
- |
| 2024 |
-1.7 |
0.03 |
0.73 |
0.00 |
- |
| 2025 |
-1.0 |
0.17 |
0.64 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-1.01 |
$0.00 |
$-6.45M |
- |
| 2020 |
$-5.89 |
$138K |
$-37.74M |
-27346.4% |
| 2021 |
$-24.30 |
$0.00 |
$-156.79M |
- |
| 2022 |
$-34.46 |
$0.00 |
$-223.18M |
- |
| 2023 |
$-24.00 |
$0.00 |
$-156.09M |
- |
| 2024 |
$-11.39 |
$0.00 |
$-74.14M |
- |
| 2025 |
$-10.70 |
$0.00 |
$-71.37M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.61 |
$-1.61 – $-1.61 |
$3.98M |
$3.98M – $3.98M |
1 |
| 2027 |
$-8.28 |
$-8.28 – $-8.28 |
$8.2M |
$8.2M – $8.2M |
1 |
| 2028 |
$-11.06 |
$-11.06 – $-11.06 |
$8.44M |
$8.44M – $8.44M |
1 |
| 2029 |
$0.00 |
$0.00 – $0.00 |
$53.8M |
$53.8M – $53.8M |
0 |
